3 days Ago By ABMN Staff
DURECT Co. ( NASDAQ:DRRX – Free Report ) – Research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of DURECT in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst E.
Arce now expects that the specialty pharmaceutical company will post earnings per share of ($0.63) for the year, up from their prior estimate of ($1.07).
HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for DURECT’s current full-year earnings is ($0.64) per share.
HC Wainwright also issued estimates for DURECT’s Q4 2024 earnings at ($0.14) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.
15) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.
60) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at $0.67 EPS and FY2028 earnings at $3.
07 EPS. Separately, StockNews.com started coverage on shares of DURECT in a research note on Monday, November 11th.
They issued a “sell” rating for the company. DURECT Price Performance Shares of NASDAQ DRRX opened at $0.92 on Monday.
The company has a market cap of $28.63 million, a PE ratio of -1.51 and a beta of 1.
13. The stock has a fifty day moving average price of $1.34 and a 200 day moving average price of $1.
37. DURECT has a 1-year low of $0.48 and a 1-year high of $1.
88. Hedge Funds Weigh In On DURECT A number of large investors have recently modified their holdings of the business. Richmond Brothers Inc.
grew its holdings in DURECT by 39.5% during the second quarter. Richmond Brothers Inc.
now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after acquiring an additional 303,670 shares during the period. Accredited Investors Inc. acquired a new stake in DURECT in the second quarter valued at $113,000.
Geode Capital Management LLC boosted its position in shares of DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares in the last quarter.
International Assets Investment Management LLC grew its stake in shares of DURECT by 41.3% during the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 6,300 shares during the period.
Finally, Gagnon Securities LLC increased its holdings in shares of DURECT by 6.0% in the 1st quarter. Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock valued at $460,000 after purchasing an additional 21,425 shares in the last quarter.
28.03% of the stock is owned by hedge funds and other institutional investors. DURECT Company Profile ( Get Free Report ) DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. Further Reading Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter .
.
